Brief: Mauna Kea Receives FDA Clearance Of Cellvizio 100 Series
Jan 27 (Reuters) - Mauna Kea Technologies SAS MKEA.PA :
* MAUNA KEA TECHNOLOGIES RECEIVES FDA 510(K) CLEARANCE OF
CELLVIZIO® WITH A FLUORESCENT DYE, FLUORESCEIN, AS DRUG DEVICE
COMBINATION
Source text for Eikon: ID:nBw6Zb2F7a
Further company coverage: MKEA.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))
Recent news on Mauna Kea Technologies SA
See all newsBrief: Mauna Kea Technologies Confirms Trajectory Toward Profitability By Year-End 2027
Brief: Mauna Kea Technologies Announces Results Of Its Combined General Meeting
French and Benelux stocks-Factors to watch 21 Nov
Brief: Mauna Kea Technologies Receives NMPA Regulatory Approval In China For Its Next-Generation Cellvizio Platform
Europe Research Roundup: Craneware, Croda, Genus